Download PDF
Thromb Haemost 1995; 74(02): 770-777
DOI: 10.1055/s-0038-1649811
Original Article
Platelets
Schattauer GmbH Stuttgart

Increased Expression of Inducible Cyclooxygenase-2 in Human Endothelial Cells by Antiphospholipid Antibodies[*]

Aïda Habib
1   The I. F. R. Biologie de la Circulation-Lariboisière, U 348 INSERM, Höpital Lariboisière, Paris, France
,
Marta E Martinuzzo
2   The University Institute of Biomedical Sciences, Favaloro Foundation, Buenos Aires, Argentina
,
Luis O Carreras
2   The University Institute of Biomedical Sciences, Favaloro Foundation, Buenos Aires, Argentina
,
Sylviane Lévy-Toledano
1   The I. F. R. Biologie de la Circulation-Lariboisière, U 348 INSERM, Höpital Lariboisière, Paris, France
,
Jacques Maclouf
1   The I. F. R. Biologie de la Circulation-Lariboisière, U 348 INSERM, Höpital Lariboisière, Paris, France
› Author Affiliations
Further Information

Publication History

Received 12 January 1995

Accepted after revision 09 March 1995

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effect of IgGs from 4 patients with antiphospholipid antibodies and elevated excretion of urinary 11-dehydro-thromboxane B2 was evaluated on the production of prostacyclin by human endothelial cells in culture. After 6 h incubation, there was no change in 6-keto-prosta-glandin F1α in the supernatant. However patients’ IgGs induced a marked increase in cyclooxygenase (Cox) activity compared to IgGs from 2 normal individuals or a commercial pool of IgGs from normal donors, tested by adding exogenous arachidonic acid. Western blot analysis of the cellular Cox content using antibodies specific for the different forms of the enzymes revealed that patients’ IgGs stimulated the synthesis of the newly described inducible Cox-2 without affecting the constitutive Cox-1. This effect was partially neutralized by preincubating the IgGs with phospholipids. The induction was dependent on the amount of IgGs; it was visible at 2 h and persisted up to 24 h. Analysis of mRNA levels showed a pattern of variation in good agreement with the results obtained for protein. The protein kinase inhibitor H-7 or long-term incubation of cells with PMA strongly reduced the induction. These results suggest that antiphospholipid antibodies may not prevent the potential of the vascular cells from generating higher amounts of prostacyclin in response to acute episodes of thrombosis.

* This work was performed as part of an exchange program between the Institut National de la Santé et de la Recherche Médicale, France (INSERM) and the Consejo Nacional de Investigaciones Científicas y Técnicas de la República Argentina (CONICET), and was supported in part by grants from INSERM and from the Association pour la Recherche sur le Cancer (ARC) (grant 2076). A. H. is supported by a scholarship from Association Sanofi Thrombose pour la Recherche (Sanofi, Paris).


 

  • References

  • 1 Carreras LO, Maclouf J. The lupus anticoagulant and eicosanoids. Prostaglandins, Leukotrienes and Essential Fatty Acids 1993; 49: 483-488
    CrossrefPubMedGoogle Scholar
  • 2 Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B, Van Assche A. Recurrent arterial thrombosis, repeated intrauterine death and ”lupus” anticoagulant. Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-246
    PubMedGoogle Scholar
  • 3 Carreras LO, Vermylen JG. ”Lupus” anticoagulant and thrombosis. Possible role of inhibition of prostacyclin formation Thromb Haemost 1982; 48: 38-40
    PubMedGoogle Scholar
  • 4 Carreras LO, Vermylen J, Spitz B, Van Assche A. ”Lupus” anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death. Br J Obstet Gynaecol 1981; 88: 890-894
    CrossrefPubMedGoogle Scholar
  • 5 Elias M, Eldor A. Thromboembolism in patients with the ”lupus” type circulating anticoagulant. Arch Intern Med 1984; 144: 510-515
    CrossrefPubMedGoogle Scholar
  • 6 de Castellarnau C, Vila L, Sancho MJ, Borrell M, Fontcuberta J, Rutllant ML. Lupus anticoagulant, recurrent abortion, and prostacyclin production by cultured smooth muscle cells. Lancet 1983; 2: 1137-1138
    PubMedGoogle Scholar
  • 7 Schorer AE, Wickham NW R, Watson KV. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol 1989; 71: 399-407
    PubMedGoogle Scholar
  • 8 Schorer AE, Duane PG, Woods VL, Niewoehner DE. Some antiphospholipid antibodies inhibit phospholipase A2activity. J Lab Clin Med 1992; 120: 67-77
    PubMedGoogle Scholar
  • 9 Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells. Inhibition of thrombomodulin-dependent protein C activation Thromb Haemost 1988; 60: 54-58
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium-associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res 1988; 51: 267-281
    CrossrefPubMedGoogle Scholar
  • 11 Petraiuolo W, Bovill E, Hoak J. The lupus anticoagulant stimulates the release of prostacyclin from human endothelial cells. Thromb Res 1988; 50: 847-855
    CrossrefPubMedGoogle Scholar
  • 12 Hasselaar P, Derksen RH W M, Blokzijil L, de GrootPG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemost 1988; 59: 80-85
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
    CrossrefPubMedGoogle Scholar
  • 14 Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 1991; 78: 2894-2899
    PubMedGoogle Scholar
  • 15 Martinuzzo ME, Maclouf J, Carreras LO, Lévy ToledanoS. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-F191
    PubMedGoogle Scholar
  • 17 Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-7388
    CrossrefPubMedGoogle Scholar
  • 18 Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase Type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-9054
    PubMedGoogle Scholar
  • 19 Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-25938
    CrossrefPubMedGoogle Scholar
  • 20 Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the C-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 268: 23448-23454
    PubMedGoogle Scholar
  • 21 Forastiero RR, Falcón CR, Carreras LO. Comparison of various screening and confirmatory tests for the detection of the lupus anticoagulant. Haemostasis 1990; 20: 208-214
    PubMedGoogle Scholar
  • 22 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65: 320-322
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Harris EN. The second international anticardiolipin standardization workshop. The Kingston antiphospholipid antibody study (KAPS) group Am J Clin Pathol 1990; 94: 476-484
    CrossrefPubMedGoogle Scholar
  • 24 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756
    CrossrefPubMedGoogle Scholar
  • 25 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassay of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-1173
    CrossrefPubMedGoogle Scholar
  • 26 Zhang SZ, Lipsky MM, Trump BF, Hsu IC. Neutral red assay for cell viability and xenobiotic-induced cytotoxicity in primary cultures of human and rat hepatocytes. Cell Biology and Toxicology 1990; 6: 219-234
    PubMedGoogle Scholar
  • 27 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 28 Towbin H, Stahelin T, Gordon J. Electrophoresic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4357
    CrossrefPubMedGoogle Scholar
  • 29 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159
    PubMedGoogle Scholar
  • 30 Fourney RM, Miyakoshi J, Day IIIR S, Paterson MC. Northern blotting: efficient RNA staining anil transfer. Pocus 1988; 10: 5-7
    PubMedGoogle Scholar
  • 31 Arcari P, Martinelli R, Salvatore F. The complete sequence of a full length cDNA for human liver glyeeralilehyile-3-phosphate dchydrogc nase: evidence for multiple mRNA species. Nucl Acid Res 1984; 12: 9179-9189
    CrossrefPubMedGoogle Scholar
  • 32 Feinberg A, Volgelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity (addendum). Anal Biochem 1984; 137: 266-267
    CrossrefPubMedGoogle Scholar
  • 33 Pierangeli SS, Harris EN, Gharavi AE, Goldsmith G, Branch DW, Dean WL. Are immunoglobulins with lupus anticoagulant activity specific for phospholipids. Br J Haematol 1993; 85: 124-132
    CrossrefPubMedGoogle Scholar
  • 34 Galli M, Comfurius P, Maassen C, Hemker HC, de BaetsM H, Breda-Vriesman vanP J C, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
    CrossrefPubMedGoogle Scholar
  • 35 Me Neil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β-glyeoprolein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 80: 4120-4124
    PubMedGoogle Scholar
  • 36 Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygcnasc homologue. J Biol Chem 1991; 266: 12866-12872
    CrossrefPubMedGoogle Scholar
  • 37 Moatter T, Gerritsen ME. Fibroblast growth factor uprcgulates PGG/H synthase in rabbit microvaseular endothelial cells bya glucocorticoid- independent mechanism. J Cell Physiol 1992; 151: 571-578
    CrossrefPubMedGoogle Scholar
  • 38 Ballou LR, Chao CP, Holness MA, Barker SC, Raghow R. Intcrleukin-t-mediated PGE2production and shingomyelin metabolism. Evidence for the regulation of cyclooxygenasegene expression by sphingosine and ceramide J Biol Chem 1992; 267: 20044-20050
    PubMedGoogle Scholar
  • 39 Oosting JD, Derksen RH W M, Entjes HT I, Bouma BN, deGroot PG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67: 499-502
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri D, Di MunnoO, Tatarelli G, Cinotti GA, Simonetti BM, Pierueei A. Functional significance of renal prostacyclin and thromboxane A2production in patients with systemic lupus erythematosous. J Clin Invest 1985; 76: 1011-1108
    CrossrefPubMedGoogle Scholar
  • 42 Violi F, Davi G, Ferro D, Valesini G, Lulano H, Leo R, Patrono C. Thromboxane biosynthesis in patients with systemic lupus erythematosus. Thromb llaemost 1993; 69: 541 abstract
    PubMedGoogle Scholar
  • 43 Arfors L, Vesterqvist O, Johnsson H, Green K. Increased thromboxane formation in patients with antiphospholipid syndrome. Eur J Clin Invest 1990; 20: 607-612
    PubMedGoogle Scholar
  • 44 FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. New Engl J Med 1984; 310: 1065-1068
    CrossrefPubMedGoogle Scholar
  • 45 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. New Engl J Med 1986; 315: 983-989
    CrossrefPubMedGoogle Scholar
  • 46 Reilly IAG, Roy L, FitzGerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud’s phenomenon. Br Med J 1986; 292: 1037-1039
    CrossrefPubMedGoogle Scholar
  • 47 Ross R. The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature 1993; 362: 801-809
    CrossrefPubMedGoogle Scholar